All In Biotech

Drug Trial Radar · NCT06118086

Study of REM-422 in Patients With Recurrent, Metastatic, or Unresectable Adenoid Cystic Carcinoma

A Phase 1/2, Multicenter, Open-label Study of REM-422, a MYB mRNA Degrader, in Patients With Recurrent, Metastatic, or Unresectable Adenoid Cystic Carcinoma

Last checked: Nov 19, 2026Latest source record: Jun 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

125

Planned (sponsor's estimate)

Start

Dec 20, 2023

Primary completion

Sep 30, 2027

Study completion Sep 30, 2027

Sponsor

Lead sponsor
Remix TherapeuticsIndustry
Sponsor type
Industry
First posted
Nov 7, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this study is to determine the safety and antitumor effects of REM-422, a MYB mRNA degrader, in people with advanced Adenoid Cystic Carcinoma (ACC)

Conditions

  • Adenoid Cystic Carcinoma
  • Metastatic Adenoid Cystic Carcinoma
  • Recurrent Adenoid Cystic Carcinoma

Interventions

  • REM-422Drug

    * REM-422 is a first in class, small molecule mRNA inhibitor that reduces expression of the MYB transcription factor * REM-422 will be administered orally once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Frequency and severity of Treatment Emergent Adverse Events (TEAEs)Time frame: 18 months
  2. Overall Response Rate (ORR) in Phase 2 Confirmatory CohortTime frame: 18 months
  3. Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D)Time frame: Assessed at the end of Cycle 1 for each participant

Locations

9 sites in 2 countries. Site status is shown where the registry gives one.

  • University of California San Francisco Helen Diller Comprehensive Cancer Center

    San Francisco, California · Recruiting

  • Moffitt Cancer Center

    Tampa, Florida · Recruiting

  • Dana Farber Cancer Research Institute

    Boston, Massachusetts · Recruiting

  • University of Michigan Rogel Cancer Center

    Ann Arbor, Michigan · Recruiting

  • Memorial Sloan Kettering Cancer Center

    New York, New York · Recruiting

  • Sarah Cannon Research Institute

    Nashville, Tennessee · Recruiting

  • MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • Centre Antoine Lacassagne

    Nice, France · Recruiting

  • Institut de Cancerologie Gustave-Roussy

    Villejuif, France · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.